Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674. https://doi.org/10.1016/J.CELL.2011.02.013

Article  CAS  PubMed  Google Scholar 

Ljunggren HG, Jonsson R, Höglund P (2018) Seminal immunologic discoveries with direct clinical implications: the 2018 Nobel Prize in Physiology or Medicine honours discoveries in cancer immunotherapy. Scand J Immunol. https://doi.org/10.1111/SJI.12731

Article  PubMed  Google Scholar 

Chen DS, Mellman I (2017) Elements of cancer immunity and the cancer–immune set point. Nature 541(7637):321–330. https://doi.org/10.1038/nature21349

Article  CAS  PubMed  Google Scholar 

Ghosh C, Luong G, Sun Y (2021) A snapshot of the PD-1/PD-L1 pathway. J Cancer 12:2735. https://doi.org/10.7150/JCA.57334

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiang X, Wang J, Deng X et al (2019) Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer 18:1–17. https://doi.org/10.1186/S12943-018-0928-4

Article  CAS  Google Scholar 

Song MK, Park BB, Uhm J (2019) Understanding immune evasion and therapeutic targeting associated with PD-1/PD-L1 pathway in diffuse large B-cell lymphoma. Int J Mol Sci 20:1326. https://doi.org/10.3390/IJMS20061326

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim JM, Chen DS (2016) Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Ann Oncol 27:1492–1504. https://doi.org/10.1093/ANNONC/MDW217

Article  CAS  PubMed  Google Scholar 

Silveira DA, Ribeiro FM, Simão ÉM et al (2021) Expression of genes and pathways associated with the B7-CD28 superfamily in response to irradiation of blood cells using 137Cs. Int J Radiat Biol 97:149–155. https://doi.org/10.1080/09553002.2021.1857454

Article  CAS  PubMed  Google Scholar 

Rezayi M, Hosseini A (2023) Structure of PD1 and its mechanism in the treatment of autoimmune diseases. Cell Biochem Funct 41:726–737. https://doi.org/10.1002/CBF.3827

Article  CAS  PubMed  Google Scholar 

Lai X, Li R, Wang P et al (2023) Cumulative effects of weakly repressive regulatory regions in the 3’ UTR maintain PD-1 expression homeostasis in mammals. Commun Biol 6:1–13. https://doi.org/10.1038/s42003-023-04922-y

Article  CAS  Google Scholar 

Malinowska K, Kowalski A, Merecz-Sadowska A et al (2023) PD-1 and PD-L1 expression levels as a potential biomarker of chronic rhinosinusitis and head and neck cancers. J Clinl Med 12:2033. https://doi.org/10.3390/JCM12052033

Article  CAS  Google Scholar 

Chen R-Y, Zhu Y, Shen Y-Y et al (2023) The role of PD-1 signaling in health and immune-related diseases. https://doi.org/10.3389/fimmu.2023.1163633

Buchbinder EI, Desai A (2016) CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol 39:98–106. https://doi.org/10.1097/COC.0000000000000239

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang Y, Zheng J (2020) Functions of immune checkpoint molecules beyond immune evasion. Adv Exp Med Biol 1248:201–226. https://doi.org/10.1007/978-981-15-3266-5_9

Article  CAS  PubMed  Google Scholar 

Zhang K, Kong X, Li Y et al (2022) PD-1/PD-L1 inhibitors in patients with preexisting autoimmune diseases. Front Pharmacol. https://doi.org/10.3389/FPHAR.2022.854967

Article  PubMed  PubMed Central  Google Scholar 

Chen RY, Zhu Y, Shen YY et al (2023) The role of PD-1 signaling in health and immune-related diseases. Front Immunol 14:1163633. https://doi.org/10.3389/FIMMU.2023.1163633/BIBTEX

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boussiotis VA, Chatterjee P, Li L (2014) Biochemical signaling of PD-1 on T cells and its functional implications. Cancer J 20:265–271. https://doi.org/10.1097/PPO.0000000000000059

Article  CAS  PubMed  PubMed Central  Google Scholar 

Patsoukis N, Duke-Cohan JS, Chaudhri A et al (2020) Interaction of SHP-2 SH2 domains with PD-1 ITSM induces PD-1 dimerization and SHP-2 activation. Commun Biol. https://doi.org/10.1038/S42003-020-0845-0

Article  PubMed  PubMed Central  Google Scholar 

Shimizu K, Sugiura D, Okazaki IM et al (2021) PD-1 preferentially inhibits the activation of low-affinity T cells. Proc Natl Acad Sci U S A. https://doi.org/10.1073/PNAS.2107141118

Article  PubMed  PubMed Central  Google Scholar 

Marabelle A, Aspeslagh S, Postel-Vinay S, Soria JC (2017) JAK mutations as escape mechanisms to anti-PD-1 therapy. Cancer Discov 7:128–130. https://doi.org/10.1158/2159-8290.CD-16-1439

Article  CAS  PubMed  Google Scholar 

Niogret C, Birchmeier W, Guarda G (2019) SHP-2 in lymphocytes’ cytokine and inhibitory receptor signaling. Front Immunol. https://doi.org/10.3389/FIMMU.2019.02468

Article  PubMed  PubMed Central  Google Scholar 

Ando S, Perkins CM, Sajiki Y et al (2023) mTOR regulates T cell exhaustion and PD-1-targeted immunotherapy response during chronic viral infection. J Clin Invest. https://doi.org/10.1172/JCI160025

Article  PubMed  PubMed Central  Google Scholar 

Simon S, Labarriere N (2018) PD-1 expression on tumor-specific T cells: friend or foe for immunotherapy? Oncoimmunology. https://doi.org/10.1080/2162402X.2017.1364828

Article  Google Scholar 

Thibult ML, Mamessier E, Gertner-Dardenne J et al (2013) PD-1 is a novel regulator of human B-cell activation. Int Immunol 25:129–137. https://doi.org/10.1093/INTIMM/DXS098

Article  CAS  PubMed  Google Scholar 

Quatrini L, Mariotti FR, Munari E et al (2020) The immune checkpoint PD-1 in natural killer cells: expression, function and targeting in tumour immunotherapy. Cancers (Basel) 12:1–21. https://doi.org/10.3390/CANCERS12113285

Article  Google Scholar 

Zhang H, Liu L, Liu J et al (2023) Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers. Mol Cancer 22:58. https://doi.org/10.1186/S12943-023-01725-X

Article  PubMed  PubMed Central  Google Scholar 

Oh SA, Wu DC, Cheung J et al (2020) PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer. Nat Cancer 1:681–691. https://doi.org/10.1038/S43018-020-0075-X

Article  CAS  PubMed  Google Scholar 

Strauss L, Mahmoud MAA, Weaver JD et al (2020) Targeted deletion of PD-1 in myeloid cells induces antitumor immunity. Sci Immunol. https://doi.org/10.1126/SCIIMMUNOL.AAY1863

Article  PubMed  PubMed Central  Google Scholar 

Sandhu HS, Hemmati HD, Dana R (2020) Immune checkpoint inhibitors and corneal transplant rejection: a call for awareness. Immunotherapy 12:947. https://doi.org/10.2217/IMT-2020-0100

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oliveira AF, Bretes L, Furtado I (2019) Review of PD-1/PD-L1 inhibitors in metastatic dMMR/MSI-H colorectal cancer. Front Oncol. https://doi.org/10.3389/FONC.2019.00396